|
ovarian neoplasm
|
0.060 |
Biomarker
|
disease |
BEFREE |
To further elucidate the role of Rsf-1 in ovarian cancer, we studied Rsf-1 immunoreactivity in 294 ovarian tumors of various histologic types.
|
16938522 |
2006 |
|
ovarian neoplasm
|
0.060 |
Biomarker
|
disease |
BEFREE |
Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer.
|
19190325 |
2009 |
|
ovarian neoplasm
|
0.060 |
Biomarker
|
disease |
BEFREE |
These data suggest that Rsf-1/HBXAP gene-transduced DCs may be a potential adjuvant immunotherapy for ovarian cancer in clinical applications.
|
20226169 |
2010 |
|
ovarian neoplasm
|
0.060 |
Biomarker
|
disease |
BEFREE |
In summary, amplification of these four putative oncogenes from 11q13 in early ovarian cancer is associated with a serous histology and in the case of EMSY and RSF1 a poor outcome.
|
18314909 |
2008 |
|
ovarian neoplasm
|
0.060 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings indicate an important role of Rsf-1 amplification in ovarian cancer.
|
16172393 |
2005 |
|
Tumor Progression
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Dysregulated RSF1 has been reported to be related to tumor progression.
|
28843909 |
2017 |
|
Tumor Progression
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Our data suggest that Rsf-1 participates in tumor progression in CCC, and indicates that the contribution of Rsf-1 to disease aggressiveness deserves further study.
|
21131837 |
2011 |
|
Tumor Progression
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Rsf-1 (HBXAP) was recently reported to play roles in tumorigenesis and tumor progression.
|
28289901 |
2017 |
|
Tumor Progression
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Our previous studies demonstrated requirement of Rsf-1 for cell survival in cancer cells, which contributed to tumour progression; however, its role in tumourigenesis has not yet been elucidated.
|
23378270 |
2013 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
HBXAP is a novel cellular nuclear protein containing a PHD (plant homology domain) finger, a domain shared by many proteins that play roles in chromatin remodeling, transcription coactivation, and oncogenesis. pX physically interacts with HBXAP in vitro and in vivo via the HBXAP region containing the PHD finger.
|
11788598 |
2002 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Rsf-1 (HBXAP) was recently reported to play roles in tumorigenesis and tumor progression.
|
28289901 |
2017 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
We extensively characterized RSF-1, a driver identified by Helios whose amplification correlates with poor prognosis, and found increased tumorigenesis and metastasis in mouse models.
|
25433701 |
2014 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Hepatitis B virus x associated protein (HBXAP), as a subunit of chromatin remodeling and spacing factor, plays a critical role in cancer development through gene amplification.
|
23456648 |
2013 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Rsf-1 (HBXAP) has been reported as an amplified gene in human cancer, including the highly aggressive ovarian serous carcinoma.
|
20923775 |
2010 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Our previous studies demonstrated requirement of Rsf-1 for cell survival in cancer cells, which contributed to tumour progression; however, its role in tumourigenesis has not yet been elucidated.
|
23378270 |
2013 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
RSF-1 can be used as a potential new therapeutic target for the treatment of breast cancer.
|
30214561 |
2018 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
CCND1 gene amplification was observed in 8.7% and RSF1 in 6.8% of these patients, preferentially in estrogen receptor-positive breast cancers.
|
24367492 |
2013 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Because the Rsf-1 amplicon overlaps an amplified region reported in breast cancer, we included 782 neoplastic and normal breast tissues for comparison.
|
16938522 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
This study assessed the function of Rsf-1 in the modulation of the sensitivity of NSCLC to paclitaxel via the NF-κB pathway.
|
29258089 |
2017 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
We extensively characterized RSF-1, a driver identified by Helios whose amplification correlates with poor prognosis, and found increased tumorigenesis and metastasis in mouse models.
|
25433701 |
2014 |
|
Malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, Rsf-1 is overexpressed in NSCLC and contributes to malignant cell growth by cyclin D1 and ERK modulation, which makes Rsf-1 a candidate therapeutic target in lung cancer.
|
22387541 |
2012 |
|
Malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, quantification of serum HBXAP DNA by FQ-PCR could potentially serve as a novel complementary tool for the clinical screening and detection of lung cancer.
|
23456648 |
2013 |
|
Carcinoma of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, Rsf-1 is overexpressed in NSCLC and contributes to malignant cell growth by cyclin D1 and ERK modulation, which makes Rsf-1 a candidate therapeutic target in lung cancer.
|
22387541 |
2012 |
|
Carcinoma of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, quantification of serum HBXAP DNA by FQ-PCR could potentially serve as a novel complementary tool for the clinical screening and detection of lung cancer.
|
23456648 |
2013 |
|
Primary malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, Rsf-1 is overexpressed in NSCLC and contributes to malignant cell growth by cyclin D1 and ERK modulation, which makes Rsf-1 a candidate therapeutic target in lung cancer.
|
22387541 |
2012 |